Through automated processing of diffusion-weighted magnetic resonance imaging (MRI) scans, the Advanced Neuro Diagnostic Imaging (ANDI) software performs detailed analysis of white matter microstructure.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Advanced Neuro Diagnostic Imaging (ANDI, Imeka), an artificial intelligence (AI)-enabled neuroimaging software that provides mapping of white matter microstructure on diffusion magnetic resonance imaging (MRI).
Employing a combination of modelling reconstruction algorithms, fiber bundling and tractography, the ANDI software platform assesses the microstructure of connecting white matter bundles through automated processing of diffusion-weighted MRI, according to Imeka.
The company said the ANDI software provides detailed analysis of the micro- and macrostructural values of white matter bundles and produces a subsequent DICOM-encapsulated PDF report noting white matter bundles that may have significant deviation from normative values.
“Imeka is pioneering AI in diffusion MRI-based white matter imaging to evaluate microstructural properties of white matter in greater detail than any other techniques,” noted Jean-Rene Belanger, the chief executive officer of Imeka.
Imeka added that recently announced CPT 3 codes from the American Medical Association (AMA) are geared toward quantitative brain MRI assessment and should facilitate reimbursement for use of the ANDI software.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.